Drug Approval | July 02, 2024
Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for recurrent endometrial cancer
Imfinzi also recommended for patients with mismatch repair deficient disease
Imfinzi also recommended for patients with mismatch repair deficient disease
Aster CMI Hospital has successfully implemented several key digital health initiatives contributing to this accreditation
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
This strategic decision will unlock significant value for our scientific and industrial products business
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Subscribe To Our Newsletter & Stay Updated
